Nick Tobin

Research data Liason, Karolinska Institutet

Keywords
Key Publications
Decoding Cell Cycle Phase Variations in Cancer Hallmarks Across Breast Cancer Subgroups
2025
Clinically relevant gene signatures provide independent prognostic information in older breast cancer patients
2023
Reclassifying tumour cell cycle activity in terms of its tissue of origin
npj Precision Oncology, 2022
Survival analysis of pathway activity as a prognostic determinant in breast cancer
PLOS Computational Biology, 2022
Clinical and molecular characteristics of estrogen receptor-positive ultralow risk breast cancer tumors identified by the 70-gene signature.
International journal of cancer, 2022

About me

  • Principal Researcher and Team Leader with a Docent in Bioinformatics
    working at the Department of Oncology-Pathology in BioClinicum
    I completed my BSc in Biotechnology in 2004 at Dublin City University,
    Ireland, where I also successfully defended my dissertation 4 years later in
    the subject area of vascular biology. Since then I have held post-doctoral
    positions in Malmö – at the Centre for Molcular Pathology, a part of Lund
    University
  • Manchester – at the Paterson Institute for Cancer Research
  • and at Karolinkska Institutuet , Onk-Pat, all in the subject area of breast
    cancer.

Research

  • Our work involves the integration of multiple high-throughput data types
    including next generation sequncing, SNP and gene expression arrays with
    clinico-pathological information in order to perform high quality
    translational research with a breast and pan-cancer focus. Specifically we
    are interested in:
    * Determining the added prognostic or treatment predictive value of
    molecular biomarkers (including gene expression signatures) beyond that
    provided by routine clinical diagnostics
    * Understanding cell-cycle biology from a pan-cancer ‘omics data
    perspective

Teaching

  • I mainly teach in the subject area of Bioinformatics, but also run seminars
    on various aspects of cancer including its hallmarks and the utility of
    cancer gene expression signatures in a clinical setting. Of note I:
    * Have partcipated in over 12 weeks full-time pedagogic training courses
    * Have completed over 500 hours teaching undergradates (BSc),
    post-graduates (MSc and PhD) and medical professionals (MD) in both
    hands-on demonstration and lecturing roles
    * Executive board member FoTO – The Doctoral Programme in Tumour Biology and
    Oncology [Jan. 2020 – present]
    * Am responsible (Kursansvarig) for the Molecular Medicine-Oncology course
    (15 credits), a part of the Biomedicine program [June 2020 – present]
    * Director of Education (GUA) at Onk-Pat [Jan. 2021 – present]
    * Chair for the Scientific Committee of the Cancer Core Europe translational
    research Summer School [Jan. 2023 – present]

Last updated: 2024-10-07

Content Responsible: Naima Kayser Leeoza(naima.leeoza@scilifelab.se)

Help Us Improve!
We want to better match our services with your needs—take our short survey and help shape SciLifeLab’s digital future. You can also join our user panel for occasional feedback opportunities and early access to new tools.
Help Us Improve!
We want to better match our services with your needs—take our short survey and help shape SciLifeLab’s digital future. You can also join our user panel for occasional feedback opportunities and early access to new tools.